Published in Lancet Oncol on April 21, 2010
CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther (2011) 10.95
Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther (2011) 5.44
Personalizing medicine with clinical pharmacogenetics. Genet Med (2011) 1.73
Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. Annu Rev Pharmacol Toxicol (2014) 1.58
Are evidence standards different for genomic- vs. clinical-based precision medicine? - A quantitative analysis of individualized warfarin therapy. Clin Pharmacol Ther (2017) 1.39
Adoption of a clinical pharmacogenomics implementation program during outpatient care--initial results of the University of Chicago "1,200 Patients Project". Am J Med Genet C Semin Med Genet (2014) 1.30
Pharmacogenetics in clinical practice: how far have we come and where are we going? Pharmacogenomics (2013) 1.15
Relating human genetic variation to variation in drug responses. Trends Genet (2012) 1.05
Pharmacogenetics and cardiovascular disease--implications for personalized medicine. Pharmacol Rev (2013) 1.04
Genetic advances in medicine: has the promise been fulfilled in general practice? Br J Gen Pract (2012) 1.01
NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. Nat Genet (2016) 0.93
Pharmacogenomics in pediatric leukemia. Curr Opin Pediatr (2010) 0.93
Trends in qualifying biomarkers in drug safety. Consensus of the 2011 meeting of the spanish society of clinical pharmacology. Front Pharmacol (2012) 0.93
Management of incidental findings in clinical genomic sequencing. Curr Protoc Hum Genet (2013) 0.90
Pharmacogenomics of chemotherapeutic susceptibility and toxicity. Genome Med (2012) 0.89
Role of cytochrome P450 genotype in the steps toward personalized drug therapy. Pharmgenomics Pers Med (2011) 0.83
Statistical Optimization of Pharmacogenomics Association Studies: Key Considerations from Study Design to Analysis. Curr Pharmacogenomics Person Med (2011) 0.82
Multilocus genotypes of relevance for drug metabolizing enzymes and therapy with thiopurines in patients with acute lymphoblastic leukemia. Front Genet (2013) 0.82
Toward a clinical practice guide in pharmacogenomics testing for functional polymorphisms of drug-metabolizing enzymes. Gene/drug pairs and barriers perceived in Spain. Front Genet (2012) 0.82
Pharmacogenetic approaches in the treatment of alcohol use disorders: addressing clinical utility and implementation thresholds. Addict Sci Clin Pract (2014) 0.79
Clinical practice guidelines for translating pharmacogenomic knowledge to bedside. Focus on anticancer drugs. Front Pharmacol (2014) 0.79
Pharmacogenetics, cost of genotyping, and guidelines for individualizing therapy with mercaptopurine in pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer (2011) 0.75
HLA-DPβ1 Asp84-Lys69 antigen-binding signature predicts event-free survival in childhood B-cell precursor acute lymphoblastic leukaemia: results from the MRC UKALL XI childhood ALL trial. Blood Cancer J (2012) 0.75
Pharmacogenomics: personalizing pediatric heart transplantation. Circulation (2015) 0.75
Pharmacists should jump onto the clinical pharmacogenetics train. Am J Health Syst Pharm (2016) 0.75
CYP2C19 genetic variation and individualized clopidogrel prescription in a cardiology clinic. J Community Hosp Intern Med Perspect (2017) 0.75
The sequence of the human genome. Science (2001) 101.55
Effects of computerized physician order entry and clinical decision support systems on medication safety: a systematic review. Arch Intern Med (2003) 12.98
The incidentalome: a threat to genomic medicine. JAMA (2006) 7.24
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol (2005) 6.90
Inheritance and drug response. N Engl J Med (2003) 5.78
Medicine. Reestablishing the researcher-patient compact. Science (2007) 5.64
Medical genetics: a marker for Stevens-Johnson syndrome. Nature (2004) 5.43
Moving towards individualized medicine with pharmacogenomics. Nature (2004) 2.99
Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet (1993) 2.66
"Genetic exceptionalism" in medicine: clarifying the differences between genetic and nongenetic tests. Ann Intern Med (2003) 1.78
Pharmacogenetics and cancer therapy. Nat Rev Cancer (2001) 1.62
Pharmacogenetics of opioids. Clin Pharmacol Ther (2007) 1.59
How will GINA influence participation in pharmacogenomics research and clinical testing? Clin Pharmacol Ther (2009) 1.14
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature (2007) 17.68
Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell (2012) 12.32
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell (2002) 11.83
Treatment of acute lymphoblastic leukemia. N Engl J Med (2006) 11.30
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med (2009) 10.54
Clinical assessment incorporating a personal genome. Lancet (2010) 10.18
BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature (2008) 10.12
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature (2012) 9.89
The chemical genomic portrait of yeast: uncovering a phenotype for all genes. Science (2008) 8.52
Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med (2009) 7.95
Acute lymphoblastic leukemia. N Engl J Med (2004) 7.83
The incidentalome: a threat to genomic medicine. JAMA (2006) 7.24
Genetics. Genomic research and human subject privacy. Science (2004) 6.56
PharmGKB: the Pharmacogenetics Knowledge Base. Nucleic Acids Res (2002) 6.40
A Bayesian framework for combining heterogeneous data sources for gene function prediction (in Saccharomyces cerevisiae). Proc Natl Acad Sci U S A (2003) 6.19
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med (2014) 5.37
A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol (2009) 5.22
Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA (2009) 5.05
Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat Genet (2011) 4.93
Implementing genomic medicine in the clinic: the future is here. Genet Med (2013) 4.89
Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell (2012) 4.41
Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood (2004) 4.21
Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med (2004) 4.16
Trends in mastectomy rates at the Mayo Clinic Rochester: effect of surgical year and preoperative magnetic resonance imaging. J Clin Oncol (2009) 4.13
From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource. Biomark Med (2011) 4.05
Knowledge acquisition, consistency checking and concurrency control for Gene Ontology (GO). Bioinformatics (2003) 3.97
SAFA: semi-automated footprinting analysis software for high-throughput quantification of nucleic acid footprinting experiments. RNA (2005) 3.95
Associating genes with gene ontology codes using a maximum entropy analysis of biomedical literature. Genome Res (2002) 3.77
Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat Genet (2009) 3.71
Nonparametric methods for identifying differentially expressed genes in microarray data. Bioinformatics (2002) 3.65
Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters. J Clin Oncol (2012) 3.61
Health-information altruists--a potentially critical resource. N Engl J Med (2005) 3.61
The RNA Ontology Consortium: an open invitation to the RNA community. RNA (2006) 3.60
Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N Engl J Med (2003) 3.57
Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood (2011) 3.40
Creating an online dictionary of abbreviations from MEDLINE. J Am Med Inform Assoc (2002) 3.32
Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet (2013) 3.21
Phased whole-genome genetic risk in a family quartet using a major allele reference sequence. PLoS Genet (2011) 3.20
Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group. J Clin Oncol (2011) 3.05
Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol (2010) 3.02
Moving towards individualized medicine with pharmacogenomics. Nature (2004) 2.99
Pharmacogenomics and individualized drug therapy. Annu Rev Med (2006) 2.95
Data-driven prediction of drug effects and interactions. Sci Transl Med (2012) 2.93
Challenges in the clinical application of whole-genome sequencing. Lancet (2010) 2.92
Eukaryotic regulatory element conservation analysis and identification using comparative genomics. Genome Res (2004) 2.84
Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood (2012) 2.82
Results of therapy for acute lymphoblastic leukemia in black and white children. JAMA (2003) 2.77
Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA (2009) 2.72
PharmGKB: a logical home for knowledge relating genotype to drug response phenotype. Nat Genet (2007) 2.65
Coarse-grained modeling of large RNA molecules with knowledge-based potentials and structural filters. RNA (2009) 2.63
A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports. J Am Med Inform Assoc (2011) 2.53
Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res (2011) 2.52
Gene expression signatures predictive of early response and outcome in high-risk childhood acute lymphoblastic leukemia: A Children's Oncology Group Study [corrected]. J Clin Oncol (2008) 2.51
The Pediatric Cancer Genome Project. Nat Genet (2012) 2.49
The pharmacogenetics and pharmacogenomics knowledge base: accentuating the knowledge. Nucleic Acids Res (2007) 2.45
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin Pharmacol Ther (2013) 2.39
Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nat Genet (2013) 2.38
Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. JAMA (2007) 2.38
Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood (2010) 2.37
Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood (2013) 2.34
Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia. J Clin Oncol (2008) 2.29
Bioinformatics challenges for personalized medicine. Bioinformatics (2011) 2.28
Time to organize the bioinformatics resourceome. PLoS Comput Biol (2005) 2.25
MScanner: a classifier for retrieving Medline citations. BMC Bioinformatics (2008) 2.24
Using binning to maintain confidentiality of medical data. Proc AMIA Symp (2002) 2.23
Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol (2009) 2.20
Web-scale pharmacovigilance: listening to signals from the crowd. J Am Med Inform Assoc (2013) 2.19
Using text to build semantic networks for pharmacogenomics. J Biomed Inform (2010) 2.19
Pharmspresso: a text mining tool for extraction of pharmacogenomic concepts and relationships from full text. BMC Bioinformatics (2009) 2.15
PharmGKB: understanding the effects of individual genetic variants. Drug Metab Rev (2008) 2.09
GAPSCORE: finding gene and protein names one word at a time. Bioinformatics (2004) 2.05
Pharmacogenomics: challenges and opportunities. Ann Intern Med (2006) 1.96
Karyotypic abnormalities create discordance of germline genotype and cancer cell phenotypes. Nat Genet (2005) 1.94
The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells. Cancer Res (2009) 1.94
Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia. Cancer (2005) 1.93
Computational analysis of Plasmodium falciparum metabolism: organizing genomic information to facilitate drug discovery. Genome Res (2004) 1.92
Pharmacogenomics and bioinformatics: PharmGKB. Pharmacogenomics (2010) 1.91
Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. Blood (2012) 1.90
Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia. Blood (2008) 1.89